NeOnc Technologies (Nasdaq: NTHI) to Host Investor Conference Call to Present Data Updates from Ongoing NEO100-1 Phase 1/2a Clinical Trial and Compassionate Use Program
CALABASAS, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) — NeOnc Technologies Holdings, Inc. (NTHI) (“NeOnc” or the “Company”), a clinical-stage biopharmaceutical company developing novel brain-penetrant therapeutics for patients with malignant brain…
NeOnc Technologies Appoints Amir Heshmatpour as Chief Executive Officer to Drive Next Phase of Clinical and Corporate Growth
CALABASAS, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) — NeOnc Technologies Holdings, Inc. (NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering therapies for central nervous system (CNS)…
His Highness Sheikh Nahyan bin Zayed Al Nahyan Assumes Executive Chairmanship of NeOnc Technologies’ Subsidiary, NuroMENA, Pioneering UAE-US Partnership in Brain Cancer Treatment
CALABASAS, Calif. and ABU DHABI, United Arab Emirates, Oct. 28, 2025 (GLOBE NEWSWIRE) — NeOnc Technologies Holdings, Inc. (NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering…
NeOnc Technologies’ Subsidiary, NuroMENA, Signs Master Services Agreement with M42’s IROS and Expands Board of Directors
CALABASAS, Calif. and ABU DHABI, United Arab Emirates, Oct. 09, 2025 (GLOBE NEWSWIRE) — NeOnc Technologies Holdings, Inc. (NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering therapies for…
NeOnc Technologies and Quazar Investment Set to Close $50 Million Strategic Partnership by October 23rd Following Final UAE Tax Approvals
CALABASAS, Calif., Oct. 06, 2025 (GLOBE NEWSWIRE) — NeOnc Technologies Holdings, Inc. (NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering therapies for central nervous system (CNS)…
NeOnc Technologies Appoints Dr. David M. Ashley, Director of The Preston Robert Tisch Brain Tumor Center at Duke, to Scientific Advisory Board
CALABASAS, Calif., Oct. 02, 2025 (GLOBE NEWSWIRE) — NeOnc Technologies Holdings, Inc. (NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering therapies for central nervous system (CNS) cancers, today…
NeOnc Technologies Welcomes Dr. Alexandra M. Miller, Chief of Neuro-Oncology and Co-Director of the Brain and Spine Tumor Center at NYU Langone Health’s Perlmutter Cancer Center, to Its Scientific Advisory Board
CALABASAS, Calif., Oct. 01, 2025 (GLOBE NEWSWIRE) — NeOnc Technologies Holdings, Inc. (NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering therapies for central nervous system (CNS)…
NeOnc Technologies Appoints Renowned Neuro-Oncologist Dr. Henry S. Friedman to Scientific Advisory Board
CALABASAS, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) — NeOnc Technologies Holdings, Inc. (NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering therapies for central nervous system (CNS) cancers, today…
NeOnc Technologies to Showcase Progress on Addressing Brain Cancer to 63 Million TV Households on “Health Uncensored with Dr. Drew” on the Lifetime Network on September 25, premiering nationwide at 8:00 a.m. ET/PT
CALABASAS, Calif., Sept. 22, 2025 (GLOBE NEWSWIRE) — NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI), a multi-Phase 2 clinical-stage biotechnology company pioneering therapies for central nervous system (CNS) cancers, will be featured…
NeOnc Technologies Receives FDA Authorization to Proceed with Phase II Clinical Trial of NEO212
CALABASAS, Calif., Sept. 10, 2025 (GLOBE NEWSWIRE) – NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering therapies for central nervous system…
NeOnc Reports Second Quarter 2025 Results
CALABASAS, Calif. and ABU DHABI, United Arab Emirates, Aug. 19, 2025 – NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a multi–Phase 2 clinical-stage biotechnology company pioneering therapies for central nervous system (CNS)…
NeOnc Finalizes All Contingencies for $50 Million Strategic Partnership with Quazar Investment.
CALABASAS, Calif. and ABU DHABI, United Arab Emirates, Aug. 11, 2025: NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a multi–Phase 2 clinical-stage biotechnology company pioneering therapies for central nervous system (CNS)…
NeOnc Awarded $2.5 Million in NIH STTR Grants
Calabasas, CA – July 29, 2025 – (GLOBE NEWSWIRE) – NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a multi–Phase 2 clinical-stage biotechnology company focused on breakthrough therapies for central nervous system…
NeOnc Technologies Featured on Yahoo Finance’s Podcast Trader Talk
Calabasas, CA – July 29, 2025 – (GLOBE NEWSWIRE) – NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a multi-phase 2 clinical-stage biotechnology company advancing transformative treatments for brain and central nervous…
NeOnc To Acquire AI, 3D, and Quantum Modeling IP Portfolio from Dr. Ishwar K. Puri
US Patent 11,788,057 B2 acquired by NeOnc. Calabasas, CA – July 29, 2025 – (GLOBE NEWSWIRE) – NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a multi Phase 2 clinical-stage biotechnology company…
NeOnc Signs Definitive Agreement for $50 Million Strategic Partnership
Calabasas, CA – July 29, 2025 – (GLOBE NEWSWIRE) – NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a multi-phase 2 clinical-stage biotechnology company advancing transformative treatments for brain and central nervous…
NeOnc Technologies to Participate at the BTIG Virtual Biotechnology Conference
Calabasas, CA – July 23, 2025 – (GLOBE NEWSWIRE) – NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a clinical-stage biotechnology company advancing transformative treatments for brain and central nervous system cancers,…
NeOnc’s Executive Chairman To Be Featured In Live Interview
Calabasas, CA – July 24, 2025 – (GLOBE NEWSWIRE) – NeOnc Technologies Holdings, Inc. (NTHI), a clinical-stage biotechnology company advancing transformative treatments for brain and central nervous system cancers, is…